Basilea Pharmaceutica AG
BPMUF
$71.00
-$0.60-0.84%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.00M | 64.91M | 54.86M | 50.34M | 69.23M |
| Total Other Revenue | 15.38M | 15.36M | 8.16M | 7.48M | 6.07M |
| Total Revenue | 80.37M | 80.27M | 63.01M | 57.82M | 75.30M |
| Cost of Revenue | 51.75M | 51.69M | 37.90M | 34.78M | 36.50M |
| Gross Profit | 28.62M | 28.58M | 25.12M | 23.05M | 38.80M |
| SG&A Expenses | 11.18M | 11.16M | 10.34M | 9.48M | 9.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.93M | 62.85M | 48.23M | 44.26M | 45.59M |
| Operating Income | 17.44M | 17.42M | 14.78M | 13.56M | 29.71M |
| Income Before Tax | 16.60M | 16.58M | 11.73M | 10.76M | 30.14M |
| Income Tax Expenses | 1.31M | 1.31M | 2.15M | 1.97M | -2.23M |
| Earnings from Continuing Operations | 15.29M | 15.27M | 9.58M | 8.79M | 32.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.29M | 15.27M | 9.58M | 8.79M | 32.37M |
| EBIT | 17.44M | 17.42M | 14.78M | 13.56M | 29.71M |
| EBITDA | 18.66M | 18.63M | 15.21M | 13.96M | 30.80M |
| EPS Basic | 1.25 | 1.25 | 0.78 | 0.72 | 2.68 |
| Normalized Basic EPS | 0.85 | 0.85 | 0.60 | 0.55 | 1.56 |
| EPS Diluted | 1.18 | 1.18 | 0.77 | 0.70 | 2.39 |
| Normalized Diluted EPS | 0.77 | 0.77 | 0.53 | 0.49 | 1.36 |
| Average Basic Shares Outstanding | 12.24M | 12.24M | 12.24M | 12.24M | 12.09M |
| Average Diluted Shares Outstanding | 13.52M | 13.52M | 13.85M | 13.85M | 13.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |